These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Results of treatment with recombinant human growth hormone in children with growth retardation in end-stage renal disease].
    Author: Sieniawska M, Pańczyk-Tomaszewska M, Ziółkowska H, Jedrzejowski A, Leszczyńska B, Dyras P, Kałuzyńska A, Makulska I, Pietrzyk JA, Rubik J, Siteń G, Stachowski J, Szprynger K, Zurowska A, Roszkowska-Blaim M.
    Journal: Pol Merkur Lekarski; 2001 Apr; 10(58):263-6. PubMed ID: 11434172.
    Abstract:
    The aim of the study was to estimate the results of recombinant human growth hormone (rhGH) treatment in children with end-stage renal disease (ESRD). 60 growth retarded children with ESRD (mean age 11.2 +/- 7.2 years) were treated with rhGH at a dose of 1-1.1 IU/kg/week. The time of observation was 24 months. Thirty children completed first year, 18--second year of treatment. The mean growth velocity prior to the treatment was 3.03 +/- 1.9, during first year of the study--7.52 +/- 2.42, during second year 6.68 +/- 2.87 cm/year. The negative correlation between growth velocity and patient's age (r = -0.39; p < 0.05) suggest the better growth results in younger children during rhGH treatment. The rhGH therapy is effective method of treatment in growth retarded children with ESRD. Side effects are rare.
    [Abstract] [Full Text] [Related] [New Search]